Cellectar Biosciences, Inc.: 5%+ holders

As of November 10, 2026, 9 holders' latest Schedule 13D or 13G filings report owning 5% or more of Cellectar Biosciences, Inc. The largest reported stake is Bleichroeder LP's, at 9.99%. 17 filings are on record since July 8, 2025 (Schedule 13G, August 13, 2026).

StemPoint Capital LP also filed stake reports on 4 other companies ↓

Sell to companies like Cellectar Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-08-14 · Reporting person: SilverArc Capital Management, LLC · Sole voting: 0 · Shared voting: 851,285 · Sole dispositive: 0 · Shared dispositive: 851,285 · SCHEDULE 13G, 2026-08-14
• Filing 2026-08-14 · Reporting person: Balyasny Asset Management L.P. · Sole voting: 798,382 · Shared voting: 0 · Sole dispositive: 798,382 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-14
• Filing 2026-08-14 · Reporting person: StemPoint Capital LP · Sole voting: 0 · Shared voting: 779,976 · Sole dispositive: 0 · Shared dispositive: 845,740 · SCHEDULE 13G, 2026-08-14
• Filing 2026-08-14 · Reporting person: Caligan Partners LP · Sole voting: 0 · Shared voting: 469,998 · Sole dispositive: 0 · Shared dispositive: 469,998 · SCHEDULE 13G, 2026-08-14
• Filing 2026-08-13 · Reporting person: Bleichroeder LP · Sole voting: 808,300 · Shared voting: 0 · Sole dispositive: 808,300 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-13

Cellectar Biosciences, Inc. has 17 Schedule 13D or 13G filings on record since 2025-07-08. 9 holders' latest filing reports 5% or more of common stock, $0.00001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Cellectar Biosciences, Inc. and the warning signs.

See Cellectar Biosciences, Inc.'s free Snapshot Watch Cellectar Biosciences, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Cellectar Biosciences, Inc. and the records around it.

Cellectar Biosciences, Inc. elsewhere on the record

• Leadership changes May 2026
• Who owns it

Companies that share a holder

• StemPoint Capital LP also filed stake reports on 4 other companies: Faeth Therapeutics, Inc. (Aug 2026), Surrozen, Inc. (Aug 2026), Xilio Therapeutics, Inc. (Aug 2026)
• Hexstone Capital LLC also filed stake reports on 6 other companies: Jet.AI Inc. (Nov 2026), Actuate Therapeutics, Inc. (Oct 2026), Global Mofy AI Ltd (May 2026)
• SilverArc Capital Management, LLC also filed stake reports on 8 other companies: ELUTIA INC. (Aug 2026), TELA BIO, INC. (Aug 2026), Fractyl Health Inc (May 2026)

Want the whole picture on Cellectar Biosciences, Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Cellectar Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Cellectar Biosciences, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   18 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Cellectar Biosciences, Inc. by CUSIP 15117F880 and gives its principal executive office as 100 Campus Drive, Suite 207, Florham Park, NJ 07932 (SCHEDULE 13G, 2026-08-14).

What the percentages are based on

Each of the Reporting Persons may be deemed to be the beneficial owner of approximately 9.99% of the Shares, based on 7,991,812 Shares outstanding as of May 12, 2026, as reported in the Issuer's report filed on form 10-Q with the Securities and Exchange Commission on May 14, 2026.Balyasny Asset Management L.P., SCHEDULE 13G, 2026-08-14

Timeline

Swipe the table sideways to see every column.

Questions about who owns Cellectar Biosciences, Inc.

Who owns Cellectar Biosciences, Inc.?

On this page, 9 holders' latest ownership filings report 5% or more of Cellectar Biosciences, Inc.: Bleichroeder LP (9.99%, Schedule 13G, filed 2026-08-13), Janus Henderson Group Plc (9.99%, Schedule 13G, filed 2026-06-05), Empery Asset Management, LP (9.99%, Schedule 13G, filed 2026-08-04), SilverArc Capital Management, LLC (9.99%, Schedule 13G, filed 2026-08-14) and Balyasny Asset Management L.P. (9.99%, Schedule 13G, filed 2026-08-14); 4 more are listed above.

Who are the largest shareholders of Cellectar Biosciences, Inc.?

By the share each holder's latest filing reports, the largest holders of Cellectar Biosciences, Inc. on this page are Bleichroeder LP (9.99%), Janus Henderson Group Plc (9.99%) and Empery Asset Management, LP (9.99%).

When did Bleichroeder LP buy into Cellectar Biosciences, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Bleichroeder LP on this page is the Schedule 13G, filed 2025-11-14, reporting 6.08%; its latest, Schedule 13G filed 2026-08-13, reports 9.99%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 17 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Cellectar Biosciences, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Cellectar Biosciences, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Cellectar Biosciences, Inc. is mentioned again
• Find former Cellectar Biosciences, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes